3-(5-hydroxy-3-indolyl)quinuclidine | 137476-59-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(5-hydroxy-3-indolyl)quinuclidine
• 英文别名: 1H-Indol-5-ol, 3-(1-azabicyclo[2.2.2]oct-3-yl)-；3-(1-azabicyclo[2.2.2]octan-3-yl)-1H-indol-5-ol
• CAS: 137476-59-6
• 化学式: C₁₅H₁₈N₂O
• 分子量: 242.321
• InChiKey: RVCMYAWBNRTLIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  39.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(5-hydroxy-3-indolyl)quinuclidine 在 乙酸酐 作用下， 以 吡啶 为溶剂， 生成 3-(5-acetoxy-3-indolyl)quinuclidine
  参考文献：
  名称：

  US5227386

  摘要：

  公开号：

文献信息

• 6H-oxazolo[4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
  申请人：Schiemann Kai

  公开号：US20050101649A1

  公开（公告）日：2005-05-12

  Compounds of the formula I in which R 1 , R 2 , R 3 and R 4 are as defined in claim 1, are ligands of the nicotinic acetylcholine receptor and/or serotonergic ligands and are suitable for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia anorexia nervosa or other eating disorders, compulsvie behaviour, premenstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds, and for the treatment of disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity.

  公式I中的化合物，其中R1、R2、R3和R4如权利要求1所定义，是尼古丁乙酰胆碱受体和/或血清素配体的配体，适用于预防或治疗精神病、精神分裂症、抑郁症、焦虑状态、痴呆症，特别是阿尔茨海默病和Lewy小体痴呆、神经退行性疾病、帕金森病、肌萎缩性侧索硬化症、亨廷顿病、图雷特综合症、学习和记忆限制、暴食症厌食症或其他进食障碍、强迫行为、经前期综合症、年龄引起的记忆障碍、改善尼古丁依赖的戒断症状、中毒化合物引起的中风或脑损伤，并用于治疗其特征为循环血清素过多或血清素活性过高的疾病。
• Indole derivatives
  申请人：Merck Patent Gesellschaft mit beschrankter Haftung

  公开号：US05227386A1

  公开（公告）日：1993-07-13

  3-(3-Indolyl)quinuclidines for the formula I Ind--R I in which Ind is a 3-indolyl group which is unsubstituted or monosubstituted to tetrasubstituted by C.sub.1-4 -alkyl, trifluoromethyl, C.sub.1-4 -alkoxy, C.sub.1-4 -alkylthio, fluorine, chlorine, hydroxyl, hydroxymethyl, C.sub.6-10 -aryloxy, C.sub.7-11 -aralkyloxy, C.sub.1-5 -acyloxy, C.sub.6-10 -aroyloxy, C.sub.1-4 -alkylsulfonyloxy, C.sub.6-10 -arylsulfonyloxy, carboxyl, C.sub.1-4 -alkoxycarbonyl and/or methylenedioxy and R is 3-quinuclidinyl or 2,3-dehydro-3-quinuclidinyl, and their physiologically acceptable salts can be used as psychopharmaceuticals.

  公式I中的3-(3-吲哚基)喹诺啡啶，其中Ind是3-吲哚基基团，未取代或通过C.sub.1-4-烷基，三氟甲基，C.sub.1-4-烷氧基，C.sub.1-4-烷基硫基，氟，氯，羟基，羟甲基，C.sub.6-10-芳氧基，C.sub.7-11-芳基烷氧基，C.sub.1-5-酰氧基，C.sub.6-10-芳酰氧基，C.sub.1-4-烷基磺酰氧基，C.sub.6-10-芳磺酰氧基，羧基，C.sub.1-4-烷氧羰基和/或亚甲二氧基单取代到四取代，而R是3-喹诺啡啶基或2,3-脱氢-3-喹诺啡啶基，它们的生理上可接受的盐可用作精神药物。
• Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor liqands and/or serotonergic ligands
  申请人：——

  公开号：US20040142935A1

  公开（公告）日：2004-07-22

  Compounds of the formula (I) in which R 1 , R 2 , R 3 and R 4 are as defined in Claim 1, are ligands of the nicotinic acetylcholine receptor and/or serotonergic ligands and are suitable for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, pre-menstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence. Strokes or brain damage by toxic compounds, and for the treatment of disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity. 1

  式(I)中，R1、R2、R3和R4如权利要求1所定义的化合物是尼古丁酸乙酰胆碱受体的配体和/或5-羟色胺受体的配体，适用于预防或治疗精神病、精神分裂症、抑郁症、焦虑状态、痴呆症，特别是阿尔茨海默病和李氏小体痴呆、神经退行性疾病、帕金森病、肌萎缩性侧索硬化症、亨廷顿病、抽动症、学习和记忆障碍、贪食症、厌食症或其他进食障碍、强迫行为、经前综合征、年龄引起的记忆障碍、改善尼古丁依赖的戒断症状、中风或毒性化合物引起的脑损伤，并用于治疗其循环中5-羟色胺过多或5-羟色胺活性亢进的疾病。
• Methods of modulating neurotrophin-mediated activity
  申请人：Babinski Kazimierz

  公开号：US20070123514A1

  公开（公告）日：2007-05-31

  Disclosed are compositions which modulate the interaction with nerve growth factor and precursors thereof with neurotrophic receptors. Also disclosed are methods of using the compositions of the invention, including methods of administration.

  本发明揭示了一种调节神经生长因子及其前体与神经营养因子受体相互作用的组合物。本发明还揭示了使用该组合物的方法，包括给药方法。
• 6H-Oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
  申请人：Schiemann Kai

  公开号：US20080051394A1

  公开（公告）日：2008-02-28

  Compounds of the formula I in which R 1 , R 2 , R 3 and R 4 are as defined in Claim 1, are ligands of the nicotinic acetylcholine receptor and/or serotonergic ligands and are suitable for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, premenstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds, and for the treatment of disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity.

  公式I中的化合物，其中R1、R2、R3和R4如权利要求1所定义，是尼古丁乙酰胆碱受体和/或血清素配体的配体，适用于预防或治疗精神病、精神分裂症、抑郁症、焦虑状态、痴呆症，特别是阿尔茨海默病和Lewy小体痴呆、神经退行性疾病、帕金森病、肌萎缩性侧索硬化、亨廷顿病、抽动症、学习和记忆障碍、暴食症、厌食症或其他进食障碍、强迫行为、经前综合征、年龄引起的记忆障碍、改善尼古丁依赖的戒断症状、中毒化合物引起的中风或脑损伤，并用于治疗其特征为循环血清素过多或存在血清素活性亢进的疾病。